Compare EVTC & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVTC | MPLT |
|---|---|---|
| Founded | 1988 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2013 | 2025 |
| Metric | EVTC | MPLT |
|---|---|---|
| Price | $31.38 | $11.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $35.80 | $32.67 |
| AVG Volume (30 Days) | 382.6K | ★ 1.3M |
| Earning Date | 05-06-2026 | 05-28-2026 |
| Dividend Yield | ★ 0.67% | N/A |
| EPS Growth | 27.17 | ★ 82.39 |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $453,869,000.00 | N/A |
| Revenue This Year | $12.68 | N/A |
| Revenue Next Year | $6.86 | N/A |
| P/E Ratio | $64.70 | ★ N/A |
| Revenue Growth | ★ 11.48 | N/A |
| 52 Week Low | $21.81 | $9.10 |
| 52 Week High | $37.38 | $40.43 |
| Indicator | EVTC | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 58.40 | 28.90 |
| Support Level | $27.98 | $11.56 |
| Resistance Level | $34.41 | $20.73 |
| Average True Range (ATR) | 1.31 | 1.73 |
| MACD | -0.18 | -0.36 |
| Stochastic Oscillator | 46.43 | 38.88 |
Evertec Inc is a transaction processing business in Latin America and the Caribbean. Its business segments are Merchant Acquiring, Payment Services - Puerto Rico & Caribbean, Latin America Payments and Solutions, and Business Solutions. Latin America Payments and Solutions segment derive maximum revenue. The company serves a diversified customer base of financial institutions, merchants, corporations, and government agencies with mission-critical technology solutions that enable them to issue, process, and accept transactions securely. Geographically, it operates in Puerto Rico, Caribbean, and Latin America.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.